138423-86-6

Basic information

• Product Name: (S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid
• Synonyms: (S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid;(S)-1-tert-butyl 2-Methyl 4,4-diMethylpyrrolidine-1,2-dicarboxylate;(S)-1-Boc-4,4-dimethyl-pyrrolidine-2-carboxylic acid methyl ester;-1-tert-Butyl 2-methyl 4,4-dimethylpyrrolidine-1,2-dicarboxylate;1-tert-butyl 2-methyl (2S)-4,4-dimethylpyrrolidine-1,2-dicarboxylate
• CAS NO: 138423-86-6
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 243.3
• Mol File: 138423-86-6.mol

Chemical Properties

• Boiling Point: 345.1 °C at 760 mmHg
• Flash Point: 162.5 °C
• Appearance: /
• Density: 1.117g/cm³
• Vapor Pressure: 1.12E-05mmHg at 25°C
• Refractive Index: 1.483
• Storage Temp.: 2-8°C
• PKA: -3.26±0.60(Predicted)
• CAS DataBase Reference: (S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid(138423-86-6)
• EPA Substance Registry System: (S)-1-(tert-Butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid(138423-86-6)

Safety Data

• Hazardous Substances Data: 138423-86-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
Boc-D-Proline is used as a key intermediate in the synthesis of pharmaceuticals, particularly for the development of peptide-based drugs. Its role as a protecting group ensures the selective formation of peptide bonds, leading to the production of therapeutically relevant compounds with specific biological activities.
Used in Biochemical Research:
In biochemical research, Boc-D-Proline is employed for the synthesis of peptides and proteins with well-defined sequences. The use of Boc-D-Proline allows researchers to study the structure-function relationships of these biomolecules, contributing to a deeper understanding of their roles in various biological processes.
Used in Medical Research:
Boc-D-Proline is utilized in medical research for the development of diagnostic and therapeutic agents. Its application in peptide synthesis enables the production of bioactive peptides with potential applications in the treatment of various diseases, as well as in the development of diagnostic tools for disease detection and monitoring.
Used in Peptide Synthesis:
Boc-D-Proline is used as a protecting group in peptide synthesis to prevent unwanted reactions at the proline residue. The Boc group serves as a temporary protective measure that can be removed later in the synthesis process, ensuring the successful formation of the desired peptide sequence. This selective protection allows for the controlled synthesis of complex peptides and proteins with specific biological functions.

InChI:InChI=1/C12H21NO4/c1-11(2,3)17-10(16)13-7-12(4,5)6-8(13)9(14)15/h8H,6-7H2,1-5H3,(H,14,15)/t8-/m0/s1

Upstream product

• 138423-79-7 (R)-2-[tert-Butoxycarbonyl-(2-methyl-allyl)-amino]-3-phenylselanyl-propionic acid methyl ester 
• 158392-74-6 O₁-tert-butyl O₂-methyl (2S)-4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate 
• 98541-64-1 (S)-3-(tert-butoxycarbonylamino)-oxetan-2-one 
• 138423-74-2 (2-Methyl-allyl)-((S)-2-oxo-oxetan-3-yl)-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 

Downstream Products

• 1262400-68-9 (S)-4,4-Dimethyl-pyrrolidine-2-carboxylic acid methyl ester; hydrochloride 
• 1001353-87-2 (2S)-1-(tert-butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid 
• 1613055-95-0 C₂₀H₂₆BrNO₅ 
• 1613055-96-1 C₂₀H₂₆BrN₃O₂ 
• 1613055-97-2 C₂₆H₃₈BN₃O₄ 
• 1613055-98-3 C₃₂H₃₆F₃N₃O₅S 
• 212890-86-3 (S)-(-)-tert-butyl 2-(hydroxymethyl)-4,4-dimethylpyrrolidinecarboxylate 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS

The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X', Y, Y', A, A',Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

Preparation of 4-Alkylprolines by Intramolecular Radikal Cyclization of Chiral Serine Derivatives

N-Alkylation of the β-lactone derived from Boc-L-serine followed by ring opening with sodium benzeneselenoate provides chiral substrates which undergo intramolecular radical cyclization to afford cis/trans mixtures of 4-alkyl-L-prolines.